Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
University of Aarhus |
---|---|
Information provided by: | University of Aarhus |
ClinicalTrials.gov Identifier: | NCT00226109 |
Chronic alcoholics suffer from weak skeletal and cardiac muscle. The investigators have discovered a beneficial effect of spironolactone-treatment in that regard. Therefore, a double blind placebo controlled study is conducted, to examine the effects of spironolactone on cardiac and skeletal muscle-function in chronic alcoholics.
Condition | Intervention | Phase |
---|---|---|
Cardiomyopathy, Alcoholic Alcoholism |
Drug: spironolactone |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Effect of Spironolactone Treatment on Heart- and Skeletal Muscle in Chronic Alcoholics |
Estimated Enrollment: | 40 |
Study Start Date: | April 2004 |
Estimated Study Completion Date: | December 2008 |
Estimated Primary Completion Date: | August 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A: Active Comparator |
Drug: spironolactone
100 mg once daily. Can be reduced to 50 mg a day still maintaining the doubled-blinded status
|
Our department has done research into skeletal muscle function in patients with liver cirrhosis. Post-hoc analyses of one of these studies suggested that treatment with spironolactone had a positive effect on muscle strength and endurance. This effect was probably caused by an increase in concentration of Na, K-pumps (sodium-potassium pumps) enabling the muscle cell perform better.
To verify this finding we have designed a double-blinded, placebo-controlled, randomized clinical trial with skeletal muscle strength, -endurance, Na, K-pump content, cardiac systolic, and diastolic function as primary endpoints. Spironolactone is tested against placebo in 40 participants included among our admitted and out-clinic patients. Muscle function-tests, muscle biopsy and trans-thoracic echocardiography is performed before and after 12 weeks of treatment.
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Peter Holland-Fischer, MD | +45 24212428 | phf@svf.au.dk |
Denmark | |
Department of Medicine V (gastroenterology and hepatology) | Recruiting |
Aarhus, Denmark, 9000 | |
Contact: Peter Holland-Fischer, MD +45 24212428 phf@svf.au.dk | |
Principal Investigator: Peter Holland-Fischer, MD | |
Sub-Investigator: Niels K. Aagaard, Ph.D., MD |
Principal Investigator: | Hendrik Vilstrup, Proffessor | Univeristy of Aarhus |
Study Director: | Peter Holland-Fischer, MD | University of Aarhus |
Responsible Party: | Department of Medicine V, Aarhus University Hospital ( Peter Holland-Fischer ) |
Study ID Numbers: | AFDV01, 01 |
Study First Received: | September 23, 2005 |
Last Updated: | September 1, 2008 |
ClinicalTrials.gov Identifier: | NCT00226109 |
Health Authority: | Denmark: Danish Medicines Agency |
Alcoholism cardiomyopathy skeletal muscle |
spironolactone Na,K-pumps Magnesium |
Alcohol-Induced Disorders Heart Diseases Mental Disorders Cardiomyopathy, Alcoholic Alcoholism |
Substance-Related Disorders Disorders of Environmental Origin Alcohol-Related Disorders Cardiomyopathies Spironolactone |
Aldosterone Antagonists Natriuretic Agents Therapeutic Uses Hormone Antagonists Physiological Effects of Drugs |
Diuretics Hormones, Hormone Substitutes, and Hormone Antagonists Cardiovascular Diseases Cardiovascular Agents Pharmacologic Actions |